Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix - PubMed (original) (raw)
Clinical Trial
. 1999 Oct;17(10):3136-42.
doi: 10.1200/JCO.1999.17.10.3136.
P Fumoleau, P Fargeot, Y Krakowski, V Dieras, J Chauvergne, P Vennin, P Rebattu, H Roche, J L Misset, M A Lentz, M Van Glabbeke, A Matthieu-Boué, D Mignard, B Chevallier
Affiliations
- PMID: 10506610
- DOI: 10.1200/JCO.1999.17.10.3136
Clinical Trial
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix
C Lhommé et al. J Clin Oncol. 1999 Oct.
Abstract
Purpose: To determine the efficacy and tolerability of irinotecan (CPT-11) in advanced or recurrent cervical carcinoma.
Patients and methods: Eligible patients had histologically confirmed, inoperable, progressive, metastatic or recurrent squamous cell cervical carcinoma and had received no radiotherapy in the preceding 3 months and had never received chemotherapy. The initial irinotecan dosage of 350 mg/m(2) every 3 weeks was modifiable according to toxicity. Treatment continued for six cycles after complete response, or until disease progression or excessive toxicity after partial response, or for three additional cycles in the case of stable disease. Patients were stratified into group A (>/= one measurable lesion in a previously unirradiated area, with or without progressive disease in irradiated fields) or group B (measurable new lesion[s] in an irradiated field).
Results: Fifty-one of 55 enrolled patients were eligible for inclusion (median age, 47 years; range, 30 to 71 years). The response rate was 15.7% (95% confidence interval [CI], 7.0% to 28.6%) overall, 23.5% (95% CI, 10.7% to 41.2%) for group A (complete response, 2.9%), and zero for group B. The median time to progression and median survival were 4.0 and 8.2 months for group A and 2.5 and 4.2 months for group B, respectively. The major grade 3/4 toxicities for groups A and B were diarrhea (24.3% and 55.5%, respectively) and neutropenia (24.3% and 33.3%, respectively). There were four toxicity-related deaths, three in group B. Patients with no prior external pelvic irradiation experienced fewer grade 3 and 4 adverse events.
Conclusion: Irinotecan is effective in treating cervical squamous cell carcinoma if disease is located in an unirradiated area. Because of toxicity, a reduced dose is advised for patients previously treated with external pelvic irradiation.
Similar articles
- A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Irvin WP, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ, Potkul RK. Irvin WP, et al. Cancer. 1998 Jan 15;82(2):328-33. doi: 10.1002/(sici)1097-0142(19980115)82:2<334::aid-cncr13>3.0.co;2-#. Cancer. 1998. PMID: 9445190 Clinical Trial. - Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ. Verschraegen CF, et al. J Clin Oncol. 1997 Feb;15(2):625-31. doi: 10.1200/JCO.1997.15.2.625. J Clin Oncol. 1997. PMID: 9053486 Clinical Trial. - A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.
Look KY, Blessing JA, Levenback C, Kohler M, Chafe W, Roman LD. Look KY, et al. Gynecol Oncol. 1998 Sep;70(3):334-8. doi: 10.1006/gyno.1998.5129. Gynecol Oncol. 1998. PMID: 9790784 Clinical Trial. - Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.
Bleiberg H, Cvitkovic E. Bleiberg H, et al. Eur J Cancer. 1996;32A Suppl 3:S18-23. doi: 10.1016/0959-8049(96)00293-6. Eur J Cancer. 1996. PMID: 8943661 Review. - Irinotecan in cancers of the lung and cervix.
Sandler A, van Oosterom AT. Sandler A, et al. Anticancer Drugs. 1999 Nov;10 Suppl 1:S13-7. doi: 10.1097/00001813-199911001-00003. Anticancer Drugs. 1999. PMID: 10630363 Review.
Cited by
- Impact of programmed cell death protein 1 inhibitor therapy on the survival of patients with advanced or recurrent uterine cancers: a meta-analysis.
Liang KW, Chen LJ, Wang CH, Ma KS, Hsia LH, Wang PH. Liang KW, et al. Front Immunol. 2024 Mar 18;15:1331994. doi: 10.3389/fimmu.2024.1331994. eCollection 2024. Front Immunol. 2024. PMID: 38562939 Free PMC article. - Updates on systemic therapy for cervical cancer.
Gopu P, Antony F, Cyriac S, Karakasis K, Oza AM. Gopu P, et al. Indian J Med Res. 2021 Aug;154(2):293-302. doi: 10.4103/ijmr.IJMR_4454_20. Indian J Med Res. 2021. PMID: 35295013 Free PMC article. Review. - The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives.
Walsh RJ, Tan DSP. Walsh RJ, et al. J Clin Med. 2021 Sep 29;10(19):4523. doi: 10.3390/jcm10194523. J Clin Med. 2021. PMID: 34640541 Free PMC article. Review. - Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. de Man FM, et al. Clin Pharmacokinet. 2018 Oct;57(10):1229-1254. doi: 10.1007/s40262-018-0644-7. Clin Pharmacokinet. 2018. PMID: 29520731 Free PMC article. Review.